TNFRSF17 and plasma cell myeloma: Moreover, these authors synthesized a new carrier-based entity with the same functions as the conventional BiTEs but capable of targeting multiple antigens of multiple myeloma at once by the functionalization of the surface of liposomes with one monoclonal antibody that is directed to CD3 and other three that target the antigens BCMA, CS1, and CD38.